Greg has deep experience leading digital transformations and managing complex cybersecurity threats in diverse geopolitical environments and is recognized as a thought leader and futurist in several industries.
Here, Greg shares his thoughts on joining the company as a new wave of digital innovation promises to transform the life sciences industry from its core. He also shares what he enjoys most about his profession, explains why now it is a great time to join BMS, and describes the future of the industry from his perspective.
Q: Tell us about yourself and your family.
I was born and raised in South Jersey and went to Rutgers University for undergrad and Temple University for graduate school, but I haven’t lived in the Delaware Valley for almost 20 years, so I am thrilled to be back in the area. I love sports and, of course, I am an Eagles, Phillies, Flyers and Sixers’ fan. My wife, Kelly, and I met when we worked at Novartis 13 years ago. Back then, she was the brand manager of a product that came from Bristol Myers Squibb when it divested its consumer business. I’ve lived in New York, Arkansas, Boston, Chicago and have spent the past three and a half years with my wife and three children, Alice (11), Maddie (8) and Sarah (7), in Switzerland near the border of France and Germany. I love to ski, play tennis, strength train and code as a hobby. My wife was a nationally ranked tennis player and I have never beaten her in a match.
Q: What books and blogs are you currently reading?
I have been out of the life sciences industry for a number of years so lately I have been reading books on molecular biology, bioinformatics and biophysics to update my knowledge in those areas. In general, I am mainly consuming media through podcasts, in particular, programs focused on investing, health and nutrition. My favorites these days are “The Huberman Lab,” Lex Fridman, “Exponential View” and “Machine Learning Street Talk.”
Q: What brought you back to the healthcare industry and why now?
I have always been inspired by the purpose of the healthcare industry, but now it’s a particularly exciting time to be working for patients.
Over the last decade, we have seen unprecedented breakthroughs in many therapeutic areas, in particular in oncology, where more people are living longer with the disease than ever before. The COVID-19 pandemic demonstrated that when we work together, the industry can overcome the most complex challenges. But the outcomes of this worldwide collaboration would have not been possible without digital technologies. That’s why I decided to come back now.
I believe digital innovation, enabled by data and information technologies, have never been more relevant to the industry than now, and I am proud to see how these capabilities are embedded in so much of what our company does.
Bristol Myers Squibb’s pipeline is robust and our commitment to improving the lives of patients around the world is stronger than ever. I am honored to lead a team of professionals who are leveraging digital innovation, computer and data science to help advance this portfolio and deliver innovative medicines to patients faster.
